This AP article is such patent by-the-book allopathic/FDA propaganda that it is laughable. The FDA picks medical atavists to "review" the work of their natural enemy--i.e., anyone with a new paradigm that threatens their economic security. Stephanie Dallam, I can't believe that anyone who subscribes to these lists can be this uninformed. Therefore I ask, Who is your owner???
Vincent Gammill ---------- > From: Stephanie Dallam <[email protected]> > To: [email protected]; [email protected] > Subject: CS>Burzynski Accused of Flawed Research > Date: Thursday, October 01, 1998 9:05 AM > > Doctor Accused of Flawed Research > By TERRI LANGFORD Associated Press Writer > > HOUSTON (AP) -- The research on a controversial cancer treatment is so > flawed that it cannot be determined whether it really works, three > prominent oncologists said. > > "It is scientific nonsense," Dr. Howard Ozer, director of the > Allegheny Cancer Center in Philadelphia, said Wednesday. > > Ozer and two other physicians examined Dr. Stanislaw Burzynski's > alternative cancer treatment known as antineoplastons for the Sept. 25 > issue of The Cancer Letter, a widely read and well-respected > Washington newsletter. > > Burzynski has claimed for years that antineoplastons, compounds found > in human urine and blood, "turn off" cancer genes by interrupting > signals that cause the cells to multiply. His treatment involves > giving synthetically made antineoplastons to patients orally or > intravenously. > > Many among Burzynski's fiercely devoted clientele say they would be > dead without the therapy. > > But the other doctors who reviewed Burzynski's data say his research > parameters are "poorly designed" and his data is "not interpretable." > Those factors may preclude the public from ever knowing whether his > treatment works, the researchers say. > > In a faxed, nine-page response, Burzynski said his detractors' > findings can be attributed to their lack of complete information, > their lack of expertise, or the cancer suffered by the patient. > > "The Cancer Letter, unfortunately, is not reporting the truth and only > truth," the statement said. "It is also reporting the lies of the > oncologists who were selected by The Cancer Letter to review the > annual report (submitted to the U.S. Food and Drug Administration)." > > The three oncologists reviewed an annual report Burzynski submitted to > the FDA in an effort to obtain federal approval of his treatment. The > report included data Burzynski gathered from clinical trials of 963 > patients who received antineoplastons over a 12-month period. > > Statistics released in April and culled by the FDA from Burzynski's > preliminary reports show only 36, or 4.3 percent, of 828 patients > treated intravenously with antineoplastons responded positively to the > drug. Of the 36, 11 died. > > Burzynski's lawyer, Rick Jaffe, claimed the FDA's totals were wrong > and he chided the agency for releasing preliminary data. > > The other two physicians who evaluated the data were Peter Eisenberg, > a principal investigator with the Sutter Health West Cancer Research > Group, and Henry Friedman, chairman of the brain tumor committee of > the Pediatric Oncology Group. > > > -- > The silver-list is a moderated forum for discussion of colloidal silver. > > To join or quit silver-list or silver-digest send an e-mail message to: > [email protected] -or- [email protected] > with the word subscribe or unsubscribe in the subject: line. > > To post, address your message to: [email protected] > > List maintainer: Mike Devour <[email protected]> > -- The silver-list is a moderated forum for discussion of colloidal silver. To join or quit silver-list or silver-digest send an e-mail message to: [email protected] -or- [email protected] with the word subscribe or unsubscribe in the subject: line. To post, address your message to: [email protected] List maintainer: Mike Devour <[email protected]>
